About us
Services & Solutions
Chemistry Drug Metabolism and Pharmacokinetics (DMPK) Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Parallel Synthesis Peptide Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Fragment Based Drug Discovery (FBDD) Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH/MASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry
Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Preformulation Formulation, Analytical, and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
×

news

Company News Events Insights Webinars Virtual Tours

BioDuro Breaks Ground on 300,000 sq ft Facility in Jiangsu China

BioDuro expands its global footprint with a new 300,000 sq ft R&D facility in Jiangsu, China, bolstering drug development capabilities with 1,000 scientists
April 17, 2020

BioDuro Strengthens Senior Leadership of Global CMC Solutions Business Unit

SAN DIEGO, April 1, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, announced today the appointment of two senior leadership positions to the Global CMC Solutions bus
April 01, 2020

Congratulations to HitGen for NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial

Congratulations to HitGen for their small-molecule tyrosine kinase inhibitor HG030 and tablets (CXHL2000004、CXHL2000003) has obtained IND approval from the CDE
April 01, 2020

BioDuro Initiates Effort to Develop COVID-19 Nanobody Therapeutic

BioDuro launches a COVID-19 nanobody therapeutic program, leveraging AI and synthetic antibodies to target viral entry, supported by global health partnerships
March 26, 2020

Sundia and UChem Exhibit in the 20th Korea Organic Synthetic Society Conference

Sundia and UChem presented at the 20th Korea Organic Synthetic Society Conference, highlighting expertise in medicinal chemistry and drug discovery integration
November 21, 2019
Total 88 12...891011121314...1718
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all